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Summary: The kinetics of aluminium absorption were determined in patients with duodenal ulcer and in 2 normal
males after taking the antacid Tisacid (Biogal, Hungary). A peak serum aluminium of 54.5 μg/l was reached at
30 min, returning to the initial value of 6.8 μg/l at 3 h after the oral intake. Urinary but not serum aluminium
increased in parallel to the amount of drug taken. The serum AI values are considerably influenced by the time of
sampling. Owing to the rapid absorption and excretion of aluminium, there appears to be no danger of aluminium
deposits in the tissues or of neurological alterations, provided renal function is normal.
Introduction
Widely varying serum aluminium values are observed in
ulcer patients regularly taking the aluminium-containing
antacid, "Tisacid" (Biogal, Hungary). Preanalytical error
was considered s a possible explanation. Since no de-
tailed data are available on the absorption of antacids in
man (1—3), we carried out an experiment on ourselves,
speculating that knowledge of the time course of absorp-
tion and of the time points of sampling might help to
clarify the surprising differences in results.
Patients and Method
Serum and urinary concentratioris of aluminium were determined
in six patients with duodenal ulcer after treatment with Tisacid
(formula: Α12Μ&(ΟΗ)ι2ΟΟ3 · tH2O). It is supplied in tablets, each
containing 105.06 mg magnesium, 58.1 mg aluminium and ve-
hicles. All patients took 4 X 2 tablets in 0.11 of tap water per day.
Blood samples were generally drawn on an empty stomach prior
to, and occasionally after, the administration of Tisacid.
Two experiments were conducted on the authqrs themselves. In the
first, they took 18 tablets within 37h; in the first 8 h, 2 tablets
every 2h and then, following a break of 16h, 5 X 2 tablets at
intervals of 2 h. The serum and urinary concentration of aluminium
were determined at 6, 30 and 60 h after administration of the first
tablets. In the second experiment blood was collected in a Braun
cannula at 15, 30, 45 and 60 min, and then at 2, 3 and 4h after
the ingestion of 4 tablets of Tisacid, urine being collected for 24 h.
The aluminium concentration in l mol/1 HC1 extfacts from stools
was determined on days prior to the experiment and after the taking
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of Tisacid. The experiments were repeated after an interval of 14
days.
An oral toierance lest with 50 g glucose was performed after an
aluminium loading study. The serum aluminium concentration of
the glucose samples did not exceed 10 μg/l.
The aluminium content was determined using a Varian Spek-
trAA.20 atomic absorption spectrometer equipped with a GTA-96
graphite tube atomizer (4^-6). The results of the determinations are
given in μg/l (factor: 0.037 X μg/l = μπιοΐ/ΐ). Aluminium samples
were collected in polypropylene vessels (BCL. Lewes, Sussex,
UK), which were washed with diluted nitric acid (volume fraction
0.1) and rinsed with distilled deionized water before use to mini-
mize aluminium contamination.
Statistical analyses
A reference aluminium solutipn („1000 ppmu, = l g/l, Sigma,
USA) was used to prepare fresh Standard aluminium Solutions
daily. The calibration curve was linear with a correlation coefficient
(r2) of 0.98. The limit of detection was 6 μ§/1. The analytical me-
thod was validated by addition of a Standard solution of AI (10 to
100 μg/l) to serum. The measured aluminium concentration was
linearly related to the theoretical aluminium content, with an r2
value of 0.98. Repeated determinations showed the coefficient of
Variation to be lower thari 5% (n = 7). There was no significant
Statistical difference between the data obtained from the direct and
the Standard addition methods (t test for paired observations gave
P > 0.05). Sensitivity, s the quantity needed to give 1% absorp-
tion, was found to be 0.8 μ§/1, and for l : 5 diluted serum, 3.0 μg/l.
Data are presented s means ± SD: the serum aluminium values
of antacid-treated patients were 8.9 ± 2.1 μg/l, in the experiments
on ourselves 7.7 ± 1.5 μg/l aluminium.
120 Nagy and Jobst; Aluminium-containing antacid absorption
Rcsults
Figure l presents the aluminium values for serum and
urine observed in one of the 6 patients with duodenal
ulcer in the course of Tisacid treatment. At serum values
under 10.0 μg/l, accepted s normal, the excretion of
aluminium did not exceed the permissible concentration
of 30.0 μg/l. The serum aluminium concentration of the
other 5 Tisacid-treated patients, calculated from 34
serum samples, was 8.9 ± 2.1 μg/l. However, the three-
day value for serum aluminium was extremely and inex-
plicably high. It was this exceptionally high value of
54.5 μg/l that led us to conduct experiments on our-
selves under strictly controlled conditions.
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Fig. l Aluminium values after Tisacid treatment in 6 patients
with duodenal ulcer. The patients were given 4 X 2 tablets of Ti-
sacid (an antacid) per day for 14 days. (+) indicates the serum,
and (O) the urinary aluminium value of l of the 6 patients. The
surprisingly high value of 54.5 μg/l on day 3 (P < 0.01) was due
to the inappropriate time of sampling. The serum aluminium con-
centration of the other 5 patients was 8.9 ± 2.1 μg/l.
Figure 2 summarizes the results of the first of this kind
of investigation. At normal, constant serum aluminium
values, the urinary aluminium content inereased in pro-
portion to the intake of Tisacid. From this we concluded
that the absorption of aluminium occurred at 2 h before
sampling. Figure 3 shows the results of the second
examination, s well s presenting the dynamics of glu-
cose absorption. As in the case of glucose, the absorption
of aluminium reaches its peak (39 μg/l) at 30 min, and
after 4 h it reverts to the initial value (6.8 μg/l; P < 0.05)
(1). In a separate experiment about 90% of the alu-
minium taken in the 4 tablets of Tisacid was recovered
in the stools collected over a period of 24 h. Thus, of
the orally administered aluminium, s little s 10% was
absorbed.
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Fig. 2 Changes expressed s μg/l for serum aluminium (+) and
urinary aluminium (o) in response to repeated intake of Tisacid.
The data were obtained from the first experiments on the authors.
The abscissa shows the number of Tisacid tablets taken, and also
the time points of their Ingestion and those of blood sampling. In
the presence of an unchanged serum aluminium concentration, the
value for urinary aluminium inereased in prpportion to the TU
sacid taken.
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Fig. 3 The kinetics of Tisacid absorption after a single dose of
Tisacid and one of glucose. The examination took place in a second
experiment on the authors. (+-4-) designates -the aluminium
content in blood samples drawn with a Braun cannula at the times
shown on the abscissa; the blood samples were obtained from one
of the authors after he had taken 4 tablets of Tisacid (= 232 mg
aluminium). The figure also presents tjie results of a 50 g glucose
tolerance test (O O).
Discussion
Our investigations explain why no elevated serum alu-
minium values have been observed by other workers
(see fig. 2). It m y be supposed that the exceptionally
high value recorded on day 3 (shown in fig. 1) reflects
the aluminium concentration of the blood .sample drawn
at 30 min after the taking of Tisacid (see fig. 3), in con-
trast to the aluminium concentrations of the other blood
samples obtained eartier or later.
The data ori the kineties of aluminium absorption call
attention to the importance of
 vthe time ipoint of ,sam-
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pling, and provide an explanation for the occasionally
extremely conflicting results. The occurrence of dialysis
dementia in renal patients who havc accumulated large
amounts ofaluminium from the water used for dialysis
is well documented (7). However, with normal renal
function, äs in our case, the limited but rapid absorption
and excretion may perhaps explain why the treatment of
ulcer patients with aluminium-containing Tisacid is not
accompanied with neurological signs and Symptoms (8).
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